ArticleThe Lancet. Oncology2016
Ipilimumab plus nivolumab for advanced melanoma.
Article in The Lancet. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- An Online Decision Aid for Patients With Metastatic Melanoma—Results of the Randomized Controlled Trial “PEF-Immun”.Deutsches Arzteblatt international · 2024Trial
- Immune-related encephalitis after immune checkpoint inhibitor therapy.The oncologist · 2025Article
- PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance.Science advances · 2023Article
- Article
- Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.PloS one · 2020Article
- Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada.PharmacoEconomics - open · 2019Article
- Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.World journal of gastroenterology · 2019Article
- Article
- The Dosage of the Derivative ofBioMed research international · 2019Article
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.Molecular cell · 2018Article
- BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.Cancer immunology, immunotherapy : CII · 2018Article
- Immune Checkpoint in Glioblastoma: Promising and Challenging.Frontiers in pharmacology · 2017Review
- Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4.OncoimmunologyArticle
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27617662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.